Acute Kidney Injury in Pediatric Patients Treated with Vancomycin and Piperacillin-Tazobactam Versus Vancomycin and Cefotaxime: A Single-center Study

Rewaa Alqurashi 1, Mawaddah Batwa 1, Bashayer Alghamdi 1, Saja Aljohani 1, Nada Zaher 1, Amal Alzahrani 1, Eman Aldigs 2, Osama Safdar 3

1. Internal Medicine, King Abdulaziz University, Jeddah, SAU 2. Medical Microbiology and Parasitology, King Abdulaziz University, Jeddah, SAU 3. Pediatrics, King Abdulaziz University, Jeddah, SAU

Corresponding author: Rewaa Alqurashi, alqurashirewaa@gmail.com

Abstract

Background

Previous literature showed a higher incidence of acute kidney injury (AKI) in pediatric patients using vancomycin + piperacillin-tazobactam compared to ceftazidime + vancomycin. Our aim was to compare the incidence of developing AKI during the use of vancomycin + ceftazidime with that during the use of vancomycin + piperacillin-tazobactam in pediatric patients.

Methods

This was a retrospective, matched cohort study that used electronic records from May 1, 2015 through April 30, 2018 for all patients aged less than 16 years who received intravenous (IV) vancomycin + piperacillin-tazobactam or cefotaxime + vancomycin for at least 72 hours. AKI was defined by Kidney Disease Improving Global Outcomes (KDIGO) guidelines. Each patient from the vancomycin + piperacillin-tazobactam group was matched 1:1 with those in the vancomycin + ceftazidime group according to their age, chronic disease, gender, and the number of concomitant nephrotoxic agents. A total of 64 cases were included. Statistical analysis was performed using descriptive statistics and binary logistic regression.

Results

AKI developed in 10 of 32 patients (31.25%) who were using vancomycin + piperacillin-tazobactam. On the other hand, 13 of 32 patients (40.62%) were using cefotaxime + vancomycin (p = 0.047). Of the 10 patients who were on vancomycin + piperacillin-tazobactam regimen, 80% developed AKI Stage I. Of the 13 patients who were using cefotaxime + vancomycin, 46% developed AKI Stage II, although no statistical significance was noted in all stages.

Conclusion

Our study showed that patients treated with cefotaxime and vancomycin showed a higher incidence of AKI than patients treated with vancomycin and piperacillin-tazobactam, although the study showed no statistical significance.

Introduction

Drug exposure plays a significant role in the destruction of kidney function. Since kidneys are mainly responsible for maintaining homeostasis in the body and eliminating waste products, they are more susceptible to xenobiotics [1]. Acute kidney injury (AKI) is characterized by an abrupt decrease in kidney function within hours due to structural damage. AKI has worse outcomes in hospitalized patients [2]. Its definition has evolved from the RIFLE (Risk, Injury, Failure, Loss of Kidney Function, and End-stage Kidney Disease) criteria and the AKIN (Acute Kidney Injury Network) classification to the Kidney Disease Improving Global Outcomes (KDIGO) classification in 2012 [3-5]. KDIGO defines AKI on the basis of serum creatinine and urine output over a specific duration. Unlike the RIFLE criteria, which included glomerular filtration rate (GFR) as an important parameter, clinical judgment was required for patients to meet the AKI, RIFLE, and AKIN criteria, which were originally developed for average-sized adults and not for children [6].

Vancomycin (VAN) is a common nephrotoxic antibiotic, which has multiple FDA-approved and off-label
clinical uses [7]. It was reported that 10% - 20% and 30% - 40% of patients had AKI caused by conventional and high doses of VAN therapy, respectively. The increased production of reactive oxygen species during oxidative stress was thought to be the most probable mechanism for its nephrotoxicity [7]. There are numerous documented risk factors that could potentiate the occurrence of VAN-induced nephrotoxicity. These risk factors include increased VAN levels (> 20 mg/L), administering high doses to patients (> 4 g/day), prolonged therapy (> 7 days), intensive care unit admittance (especially if it was a prolonged stay), and concomitant treatment with nephrotoxic agents, such as nonsteroidal anti-inflammatory drugs, loop diuretics, and more [2, 8].

Patients with suspected sepsis are at higher risk of developing drug-associated adverse effects due to the use of multiple antibiotic combinations (sepsis development in patients using VAN alone was 13.1% vs 27.2% in combination groups) [9-10]. In children under antibiotic treatment, the major adverse drug reactions were caused by β-lactams and VAN [11]. Piperacillin-tazobactam (PTZ) is an antipseudomonal antibiotic that inhibits β-lactamase and is used in combination with VAN for hospitalized patients [12]. Furthermore, cefotaxime is a third-generation cephalosporin that acts against gram-negative and some gram-positive bacteria. It is well distributed throughout the body and is excreted mainly unchanged in the urine [13]. Cefotaxime is used in combination with VAN to treat serious systemic infections (osteomyelitis, infective endocarditis, skin and soft tissue infection, and many others) [14].

Several studies have reported a higher incidence of AKI in adult patients using VAN + PTZ (VAN-PTZ) combination (16.3% to 34.8%) compared to VAN + cefepime, a fourth-generation cephalosporin (12.5% to 13.3%) [10, 15-17]. Similarly, higher rates of nephrotoxicity were observed among patients treated with VAN-PTZ compared with VAN treatment alone; however, the exact mechanism for the increased nephrotoxicity by this combination was not fully understood [18]. Moreover, a robust retrospective cohort study reported a higher incidence of AKI in pediatric patients using VAN-PTZ compared to VAN-cefepime [19].

However, there are no data regarding the incidence of AKI when cefotaxime is used in combination with VAN. Therefore, we tested the safety of VAN + cefotaxime compared to that of VAN-PTZ in a pediatric population. At the King Abdulaziz University Hospital, we prefer using cefotaxime over cefepime to avoid future cefepime resistance.

**Materials And Methods**

**Study design**

This study was approved by the Institutional Review Board (IRB) of the King Abdulaziz University Hospital (KAUH) Jeddah, Saudi Arabia. The data were collected from the pediatric system database, Phoenix Data Systems Asset Information Management System (Phoenix Data Systems, Southfield, MI), starting from May 1, 2015 to April 30, 2018. There were 1,129 medical file records of patients who had received IV VAN out of which we had to extract the data that matched our inclusion criteria.

**Study subjects**

Electronic records of all patients aged less than 16 years who received IV VAN-PTZ or IV VAN + cefotaxime for at least 72 hours were reviewed; baseline serum creatinine (measured within a week before antibiotic administration), plus daily creatinine levels during the antibiotic course were monitored. AKI was defined as an increase of serum creatinine (SCr) of > 0.3 mg/dl or an increase in SCr to ≥ 1.5 times baseline. If any patient met the criteria, he or she was defined to have AKI Stage 1, which was defined as a 1.5 to 1.9-fold increase in SCr from the baseline or SCr ≥ 0.3 mg/dL (≥ 26.5 µmol/L). Stage 2 was defined as a 2.0 to 2.9-fold increase in SCr from the baseline, while Stage 3 was defined as three-fold higher SCr or SCr ≥ 4.0 mg/dl (≥ 353.6 µmol/L).

Subject characteristics were also obtained from the records including age, gender, weight, height, chronic disease, indication for antibiotics, nephrotoxic agents, VAN trough (highest measurement that was taken in a steady-state prior to AKI development), therapy duration (at least one dose on a given day), and admittance to the intensive care unit (ICU).

Each patient from the VAN-PTZ group was matched 1:1 with those in the VAN-cefotaxime group according to their age (younger than three months, equal or between three months and one year, equal to or older than one year), chronic disease (congenital heart disease, malignancy, and others), gender, and the number of concomitant nephrotoxic agents.

**Exclusion criteria**

Patients with underlying kidney disease (preexisting renal dysfunction, structural kidney disease, undergoing dialysis, or AKI at admission) or did not have a match or who took oral VAN were excluded from the study (only patients who take IV antibiotics can be tracked properly in our hospital system). All patients who did not have a match in the other group were excluded from the study.
**Statistical analysis**

The collected data were entered using an online Google® drive form and transferred to Microsoft® Excel. Our statistical analysis was performed using the IBM® Statistical Package for Social Sciences (SPSS), v.23 software package (IBM SPSS Statistics, Armonk, NY). The incidence of developing AKI that was caused by VAN-PTZ or VAN + cefotaxime was calculated using bivariate logistic regression. Binary logistic regression was used for all variables (age, gender, weight, chronic disease, indication for antibiotics, nephrotoxic agents, VAN trough, therapy duration, and ICU admission) to determine their association with the incidence of developing AKI. We considered p-value < 0.05 as significant. All variables in each treatment group and AKI development were measured using descriptive statistics.

**Results**

One-hundred and sixty-two patients were eligible for inclusion and 93 patients were excluded from the study because no match was found in the other treatment group. Five patients were from the Tazocin - vancomycin group and were excluded because there was no match for them in the other treatment group. A total of 64 cases were included: (n = 32 for VAN-PTZ) and (n = 32 for VAN + cefotaxime).

| Characteristics                      | VAN-PTZ (n = 32) | VAN-cefotaxime (n = 32) | P-value |
|--------------------------------------|-----------------|-------------------------|---------|
| Age (years)                          | 1.33 (± 1.86)   | 1.29 (± 1.99)           | 0.492²  |
| Male                                 | 18 (56.3%)      | 18 (56.3%)              | 0.126 b |
| Female                               | 14 (43.8%)      | 14 (43.8%)              |         |
| Weight                               | 8.28 (± 6.70)   | 7.96 (± 8.46)           | 0.619 b |
| Baseline serum creatinine (mg/dl)    | 0.3315 (± 0.17) | 0.47 (± 0.29)           | 0.085 b |
| CHD                                  | 19 (59.4%)      | 19 (59.4%)              | 0.855 b |
| Malignancy                           | 1 (3.1%)        | 1 (3.1%)                | 0.678 b |
| Hypertension                         | 1 (3.1%)        | 4 (12.5%)               | 0.260 b |
| Hypotension                          | 0 (0%)          | 1 (3.1%)                | 1.000 b |
| Primary immunodeficiency             | 1 (3.1%)        | 0 (0%)                  | 1.000 b |
| Hypoalbuminemia                      | 1 (3.1%)        | 0 (0%)                  | 1.000 b |
| Others                               | 0 (0%)          | 0 (0%)                  | 1.000 b |
| Indication for antibiotics           |                 |                         |         |
| Empiric therapy                      | 9 (28.1%)       | 6 (18.8%)               | 0.115 b |
| Prophylaxis                          | 4 (12.5%)       | 7 (21.9%)               | 0.513 b |
| CNS disease                          | 1 (3.1%)        | 1 (3.1%)                | 0.999 b |
| Bacteremia                           | 3 (9.4%)        | 1 (3.1%)                | 0.641 b |
| Cardiovascular disease               | 7 (21.9%)       | 10 (31.3%)              | 0.660 b |
| Respiratory disease                  | 11 (34.4%)      | 8 (25%)                 | 0.505 b |
| GU/GI disease                        | 2 (6.3%)        | 2 (6.3%)                | 0.641 b |
| SSTI                                 | 1 (3.1%)        | 1 (3.1%)                | 0.678 b |
| Febrile neutropenia                  | 1 (3.1%)        | 0 (0%)                  | 1.000 b |
| Sepsis                               | 12 (37.5%)      | 11 (34.4%)              | 0.141 b |
| Therapy duration (days)              | 8.47 (± 3.98)   | 6.50 (± 2.83)           | 0.600 b |
| Admittance to ICU                    | 16 (50%)        | 15 (46.9%)              | 0.334 b |
| ICU duration (days)                  | 5.69 (± 4.27)   | 3.53 (± 2.85)           | 0.970 b |
As seen in Table 1, the groups were well-balanced in terms of age, gender, weight, ICU duration, concomitant administration of nephrotoxic agents, chronic disease, sepsis, and baseline creatinine.

Because sepsis contributes to the administration of multi-antibiotic combination, we included it in our matching criteria with a total number of 12 of 32 (37.5%) in the VAN-PTZ group and for the other group, the total numbers were 11 out of 32 (34.4%). The baseline creatinine in the VAN-cefotaxime group was higher than that in the VAN-PTZ group, although the association between the baseline creatinine and AKI was insignificant (P = 0.065).

**AKI development in both treatment groups**

AKI was noted in 10 out of 32 patients (31.25%) who were using VAN+ PTZ and in 13 out of 32 patients (40.62%) who were using cefotaxime+ VAN, although there was no statistical significance between the two groups (p-value = 0.602) (Table 2). Most patients who were on VAN-PTZ regimen developed AKI Stage 1 (8/10, 80%), while most patients who were using cefotaxime + VAN developed AKI Stage 2 (6/13, 46%). No statistical significance was noted in all stages (Table 3).

### TABLE 1: Comparison of Clinical Characteristics in Matched Patients

| Characteristics | VAN-PTZ | VAN-cefotaxime |
|-----------------|---------|----------------|
| AKI Yes         | 10 (31.25%) | 13 (40.62%) |
| AKI No          | 22 (68.75%) | 19 (59.37%) |
| Total           | 32      | 32             |

**TABLE 2: AKI Development in Both Treatment Groups**

AKI: acute kidney injury; PTZ: piperacillin-tazobactam; VAN: vancomycin
Characteristics | VAN-PTZ (n = 32) | VAN-cefotaxime (n = 32) | Total (n = 32) | P-value |
--- | --- | --- | --- | --- |
Stage 1 | 8 (61.5%) | 5 (38.4%) | 13 (20.3%) | 0.534 |
Stage 2 | 1 (3.1%) | 6 (18.8%) | 7 (10.9%) | 0.109 |
Stage 3 | 1 (3.1%) | 2 (6.3%) | 3 (4.6%) | 1.000 |

**TABLE 3: AKI in Different Stages**

*Values shown are numbers and percentages.

AKI: acute kidney injury; PTZ: piperacillin-tazobactam; VAN: vancomycin

**Discussion**

The purpose of our study was to detect the incidence of AKI during treatment with VAN-PTZ or VAN + cefotaxime combination in pediatric age groups. In this study, the hospitalized children who were exposed to VAN + cefotaxime were at a greater risk of AKI than were children exposed to the VAN-PTZ treatment combination (40.6% vs 31.3%). To our knowledge, this is the first matched cohort study showing a difference in the incidence of AKI among diverse pediatric populations treated with this antibiotic combination.

Previous studies investigated the nephrotoxicity of those two combinations by choosing one drug (cefepime) from the cephalosporin class as an example for the entire group [17, 20], but our results were inconsistent with theirs. Cook et al. evaluated the incidence of AKI development in VAN-PTZ vs VAN + cefepime in the pediatric population (VAN-PTZ 28.9% vs VAN + cefepime 7.9%, p-value = 0.001) [19]. Another unmatched study by Gomes et al. in 2014 showed that the VAN-PTZ combination caused AKI more frequently than the VAN + cefepime combination in adults (VAN-PTZ 34.8% vs VAN + cefepime 12.5%, p-value = 0.0001) [17].

Furthermore, a study by Al Yami on adults observed the relation between VAN with PTZ or with meropenem but did not reveal significant results between the two groups with respect to AKI development (VAN-PTZ 7.41% vs VAN + meropenem 5.33%, P = 0.4) [12].

In our study, AKI was noted in 31.3% of the subjects in the VAN-PTZ group vs. 40.6% in the VAN + cefotaxime group. The results were statistically insignificant (p-value = 0.602). Most patients who used the VAN-PTZ regimen developed Stage 1 AKI (8/10, 80%), whereas most VAN + cefotaxime patients developed Stage 2 AKI (6/13, 46%); again, no statistical significance was noticed in all AKI stages. This shows that VAN + cefotaxime is as nephrotoxic as VAN-PTZ; therefore, the regimen should be used with caution, especially in children with underlying kidney disease. However, the mechanism of its nephrotoxicity is not fully understood. Additional studies are needed to validate this hypothesis. Resolution or long-term sequelae from AKI are uncertain. Data were not collected.

This study has several limitations. First, some data were difficult to obtain from the database and were taken manually (therapy duration and baseline and daily serum creatinine). Some data were missing (adjusted weighted VAN). The second issue was that this is a single-center study.

**Conclusions**

In conclusion, our study showed that cefotaxime + VAN is as nephrotoxic as VAN-PTZ. The mechanism is not understood. Since our study is the first to focus on cefotaxime + VAN, we believe that a multicentric study is necessary to confirm our results. After confirmation, we recommend decreasing the use of the VAN + cefotaxime regimen, especially in neonates, considering their immature kidneys.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained by all participants in this study. Institutional Review Board (IRB) of the King Abdullah University Hospital (KAUH) Jeddah, Saudi Arabia issued approval HA-020-I-008. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Acknowledgements

We would like to thank the Road of Change team for their constant support. We also express our gratitude to Dr. Abeer Najjar, Pediatric Infectious Diseases Consultant at King Abdulaziz University Hospital for comments that greatly improved the manuscript.

References

1. Kim SY, Moon A: Drug-induced nephrotoxicity and its biomarkers. Biomol Ther (Seoul). 2012, 20:268-72. 10.4062/biomolther.2012.20.5.268
2. Bruniera FR, Ferreira FM, Savioli LR, et al.: The use of vancomycin with its therapeutic and adverse effects: a review. Eur Rev Med Pharmacol Sci. 2015, 19:694-700.
3. Makris K, Spanou L: Acute kidney injury: definition, pathophysiology and clinical phenotypes. Clin Biochem Rev. 2016, 37:85-98.
4. Bellomo R, Ronco C, Kellum JA, Mehta MI, Palevsky P, the ADQI workgroup: Acute renal failure: definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care. 2004, 8:R204-12. 10.1186/cc2872
5. Mehta RL, Kellum JA, Shah SV, et al.: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007, 11:R31. 10.1186/cc5713
6. KDIGO Clinical Practice Guideline for Acute Kidney Injury. (2012). Accessed: January 26, 2020: http://kdro.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf.
7. Elyasi S, Khalili H, Dashi-Khavasi S, Mohammadpour A: Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012, 68:1245-55. 10.1007/s00228-012-1259-9
8. Bentley ML, Corwin HL, Dasta J: Adverse drug reactions among children over a 10-year period. Pediatrics. 2006, 118:555-62. 10.1542/peds.2005-2429
9. Al Yami MS: Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or with meropenem. J Infect Pub Health. 2017, 10:770-73. 10.1016/j.jiph.2016.11.007
10. WHO Model Prescribing Information: Drugs used in Bacterial Infections: Cefotaxime. (2001). Accessed: July 16, 2018: http://apps.who.int/medicinedocs/en/d/s5406e/16.9.html#s5406e.16.9.
11. Dilworth TJ, Ibrahim O, Hall P, Sliwinski J, Walraven C, Mercier RC: β-lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone. Antimicrob Agents Chemother. 2014, 58:102-109. 10.1128/AAC.03120-13
12. Davies SW, Efrid JT, Guidry CA, Detch ZC, Willis RN, Shah PM, Sawyer RG: Top guns: the "Maverick" and "Goose" of empiric therapy. Surg Infect (Larchmt). 2016, 17:38-47. 10.1089/sur.2015.104
13. Moenster RP, Linneman TW, Finnegan PM, Hall S, Thomas Z, McDonald JR: Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime. Clin Microbiol Infect. 2014, 20:OS84-9. 10.1111/1469-0691.12410
14. Gomes DM, Smotherman C, Birch A, Dupree L, Della Vecchia BJ, Kraemer DF, Jankowski CA: Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy. 2014, 34:662-69. 10.1002/phar.1428
15. Rutter WC, Burgess DR, Tallbert IC, Burgess DS: Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: a retrospective cohort analysis. J Hosp Med. 2017, 12:77-82. 10.12788/jhm.2684
16. Cook KM, Gillon J, Grasso AG, Banerjee R, Jimenez-Trujeque N, Phillips EI, Van Driest SL: Incidence of nephrotoxicity among pediatric patients receiving vancomycin with either piperacillin-tazobactam or cefepime: A cohort study. J Pediatric Infect Dis Soc. 2019, 8:221-27. 10.1093/jpids/piz050
17. Hammond DA, Smith MN, Painter JT, Meena NK, Luxardi K: Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam or cefepime: a retrospective cohort study. Pharmacotherapy. 2016, 36:463-71. 10.1002/phar.1738